The company will invest $24 million into its Inchinnan, Scotland, site to expand global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell-culture media.
Thermo Fisher Scientific announced it will invest $24 million into its Inchinnan, Scotland, site to expand global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell-culture media, according to a Nov. 5, 2019 company press release.
"More and more customers are outsourcing their liquid manufacturing to ensure the highest quality while delivering efficiency," said Cory Stevenson, president of Thermo Fisher's bioproduction business, in the press release. "This investment will expand capabilities and expertise at our existing cell-culture manufacturing center of excellence in the UK to meet growing customer demand for our industry-leading bioproduction products."
The expansion is set to be complete by June 2021.
Source: Thermo Fisher Scientific
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.